CVS Health Corporation has gained investor attention, with shares rising 3.6% over the past month, outperforming the S&P 500's 2.4% increase. However, the company faces challenges, as earnings estimates for the current quarter and fiscal year indicate significant declines, leading to a Zacks Rank of #5 (Strong Sell). The consensus for the next fiscal year shows a potential recovery, but recent revisions suggest caution among analysts.